Apricus Biosciences Offers Year-End '14 Update; in '15 Plans to Advance Clinical Pipeline, Further Commercialization of ED Drug Vitaros(R)

By: via Benzinga
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, ...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.